Literature DB >> 15234863

Creation of a drug fund for post-clinical trial access to antiretrovirals.

Jintanat Ananworanich1, Theshinee Cheunyam, Somsong Teeratakulpisarn, Mark A Boyd, Kiat Ruxrungtham, Joep Lange, David Cooper, Praphan Phanuphak.   

Abstract

Keywords:  Biomedical and Behavioral Research; Health Care and Public Health

Mesh：

Substances：

Year:  2004        PMID： 15234863     DOI： 10.1016/S0140-6736(04)16596-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.

Authors:  Pamela Andanda; Jane Wathuta
Journal:  Med Health Care Philos       Date:  2018-03

2.  Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.

Authors:  Jintanat Ananworanich; Meena Gorowara; Anchalee Avihingsanon; Stephen J Kerr; Nadine van Heesch; Chuleeporn Khongpetch; Anuntaya Uanithirat; Andrew Hill; Kiat Ruxrungtham; David M Burger
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

3.  Post-trial access to antiretrovirals: who owes what to whom?

Authors:  Joseph Millum
Journal:  Bioethics       Date:  2011-03       Impact factor: 1.898

4.  Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents.

Authors:  Andrea L Ciaranello; Rochelle P Walensky; Paul E Sax; Yuchiao Chang; Kenneth A Freedberg; Joel S Weissman
Journal:  HIV Clin Trials       Date:  2009 Jan-Feb

5.  Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.

Authors:  N Sofaer; C Thiessen; S D Goold; J Ballou; K A Getz; G Koski; R A Krueger; J S Weissman
Journal:  J Med Ethics       Date:  2009-03       Impact factor: 2.903

6.  Reciprocity-based reasons for benefiting research participants: most fail, the most plausible is problematic.

Authors:  Neema Sofaer
Journal:  Bioethics       Date:  2013-12-06       Impact factor: 1.898
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.